136 studies found for:    novel influenza a (h1n1)
Show Display Options
RSS Create an RSS feed from your search for:
novel influenza a (h1n1)
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Novel Influenza A (H1N1) Surveillance Registry
Conditions: Novel Influenza A;   H1N1;   Influenza
Intervention:
2 Completed Swine Flu (Novel Influenza A H1N1) Vaccine Study
Condition: Influenza
Interventions: Biological: Baxter Novel Influenza A H1N1 Whole Virus Vaccine;   Biological: GlaxoSmithKline Novel Influenza A H1N1 Split Virion Vaccine
3 Recruiting Clinical Characteristics and Outcomes in Patients Diagnosed With Novel Influenza A (H1N1)
Condition: Influenza
Intervention:
4 Completed Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1) : Multi-centre, Prospective, Randomized Controlled Study
Condition: Influenza
Interventions: Drug: oseltamivir;   Other: blank;   Drug: chinese medicinal herbs;   Drug: oseltamivir and chinese medicinal herbs
5 Unknown  Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1)Pneumonia: Multi-centre, Prospective, Randomized Controlled Study
Condition: Influenza
Interventions: Drug: oseltamivir;   Drug: oseltamivir and chinese medicinal herbs
6 Completed Antiviral Therapy for Influenza A H1N1
Condition: Influenza A Virus Infection
Intervention:
7 Completed A Clinical Trial With Influenza A/H1N1 Vaccines
Condition: Influenza
Interventions: Biological: split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose;   Biological: split-virion, adjuvanted H1N1 vaccine of 15 μg per dose;   Biological: split-virion, non-adjuvanted H1N1 vaccine of 15 μg per dose;   Biological: split-virion, non-adjuvanted H1N1 vaccine of 30 μg per dose;   Biological: whole-virion, adjuvanted H1N1 vaccine of 5 μg per dose;   Biological: whole-virion, adjuvanted H1N1 vaccine of 10 μg per dose;   Biological: placebo control
8 Completed Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Population Aged 3 Years and Older
Conditions: Virus Diseases;   Respiratory Tract Diseases;   Respiratory Tract Infections;   Influenza;   Orthomyxoviridae Infections
Interventions: Biological: split-virion, non-adjuvanted H1N1 vaccine of 30 μg;   Biological: Experimental: split-virion, adjuvanted H1N1 vaccine of 7.5 μg;   Biological: Experimental: split-virion, adjuvanted H1N1 vaccine of 15 μg;   Biological: Experimental: split-virion, adjuvanted H1N1 vaccine of 30 μg;   Biological: Experimental: split-virion, non-adjuvanted H1N1 vaccine of 15 μg;   Biological: Placebo Comparator: Placebo control
9 Unknown  Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month
Conditions: Influenza;   Swine-origin A/H1N1 Influenza
Interventions: Biological: 7.5ug H1N1 Influenza vaccine;   Biological: 15ug H1N1 vaccine;   Biological: seasonal influenza vaccine
10 Completed Observational Study of Safety of Flu Cell Culture Derived Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Vaccine
Conditions: Novel Influenza A (H1N1);   A New Flu Virus of Swine Origin
Intervention: Other: Non-intervention observational study
11 Completed
Has Results
Surveillance for Adverse Events Following Pandemic H1N1 Immunization
Condition: Novel Influenza A/H1N1
Intervention:
12 Completed
Has Results
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children
Condition: Influenza Caused by the Novel Influenza A (H1N1) Virus
Intervention: Biological: CSL425
13 Completed
Has Results
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults
Condition: Influenza Caused by the Novel Influenza A (H1N1) Virus
Intervention: Biological: CSL425
14 Enrolling by invitation Follow-up of Immunogenicity of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Healthy Volunteers After 6 Months
Condition: Influenza
Intervention:
15 Completed Observational Safety and Effectiveness Study of Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Egg Derived Vaccine
Condition: Influenza A (H1N1)
Intervention: Other: This is non-intervention observational study
16 Completed
Has Results
Relenza® Sentinel Site Monitoring Program in Japan
Condition: Influenza, Human
Intervention: Drug: zanamivir
17 Completed
Has Results
Novartis H1N1 Vaccine in Pregnant Women
Condition: Influenza
Intervention: Biological: Inactivated H1N1 Vaccine
18 Completed
Has Results
H1N1 Vaccine in Pregnant Women
Condition: Influenza
Intervention: Biological: Inactivated H1N1 Vaccine
19 Completed Safety of H1N1 Influenza Vaccination in Pregnant Women
Conditions: Virus Diseases;   Respiratory Tract Infections;   Influenza;   Orthomyxoviridae Infections
Intervention: Biological: split-virion, non-adjuvanted H1N1 vaccine of 15 μg
20 Recruiting Safety and Efficacy of Investigational Immune Plasma in Treating Influenza A
Condition: Influenza A
Interventions: Biological: Anti-Influenza Plasma;   Behavioral: Standard Care

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years